Macular Edema Treatment Market, by Disease Type (Diabetic Macular Edema and Cystoid Macular Edema), by Drug Class (Anti-Vascular Endothelial Growth Factor (VEGF) Injections (Avastin, Eylea ,and Lucentis) and Anti-inflammatory Medication (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroid Implants (Ozurdex, Retisert, and Iluvien)), by End User (Hospitals, Ophthalmic Clinics, and Research Institutes), and by Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028
Select a license type that suits your business needs
Single User License
US$ 4,500
US$ 3,500
Three thousand five hundred dollars
Frequently purchased
Multi User License
US$ 7,000
US$ 5,500
Five thousand five hundred dollars
Corporate User License
US$ 10,000
US$ 7,500
Seven thousand five hundred dollars
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients